

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number  
WO 2004/048449 A2

(51) International Patent Classification<sup>7</sup>: C08J 5/22

(21) International Application Number:  
PCT/IT2003/000780

(22) International Filing Date:  
26 November 2003 (26.11.2003)

(25) Filing Language: Italian

(26) Publication Language: English

(30) Priority Data:  
MI2002A 002501  
26 November 2002 (26.11.2002) IT

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— without international search report and to be republished upon receipt of that report

(71) Applicant and  
(72) Inventor: PETRESCU, Dorin, Olimpiu [IT/IT]; Viale Cassiodoro, 4, I-20145 Milano (IT).

(74) Agent: PIZZOLI, Pasquale; Società Italiana Brevetti S.p.A., Via Carducci, 8, I-20123 Milano (IT).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR MANUFACTURING FIBRIN MEMBRANES AND FIBRIN MEMBRANES OBTAINED ACCORDING TO THIS PROCESS



(57) Abstract: A process for manufacturing a fibrin membrane from blood plasma that was partially depleted and subjected to coagulation by adding a solution of a physiological coagulating agent, leaving the mixture to stay until forming a gelatinous blood clot, and then dehydrating said blood clot to obtain a fibrous membrane, which is subjected to washing with softening agents and then to drying until obtaining a flexible and mouldable membrane. The membrane so obtained is capable to provide an immediate and complete haemostasis, followed by a whole reabsorption, without risk of adhesions with the neighboring tissues, up to the cicatrization of the injured tissue. The membrane is mouldable and elastic, and is provided with high mechanical properties. It may be soaked with disinfectant agents, drugs or tissue growth factors.

WO 2004/048449 A2

- 1 -

"PROCESS FOR MANUFACTURING FIBRIN MEMBRANES AND FIBRIN  
MEMBRANES OBTAINED ACCORDING TO THIS PROCESS"

The present invention relates to the medical-surgical field, and in particular  
5 to a process for manufacturing fibrin membranes to be used as supports having  
high adhesiveness on human and animal tissues in cicatrisation and haemostasis  
processes, and a fibrin membrane obtained according to this process.

It is known that in medical-surgical applications, means for timely stopping  
haemorrhages, such as for example those due to external superficial wounds or  
10 lesions resulting from surgical operations, are of primary importance. It is  
necessary that said means are perfectly sterile and completely compatible with the  
organism whereon they will be applied. In the publication of J. Travis, "Buildings  
better bandages", Science News On Line, 1999, 155 (25):396, the need of new  
haemostatic means that are effective with respect to known dressings made with  
15 different kinds of fabrics (gauzes, bandages, etc.) is pointed out.

As a result of such needs, the idea of using fabrics or tissues soaked in high  
concentrations with natural proteins involved in blood coagulation was already  
developed, and has achieved first positive results. The use of a fibrin tissue  
provides an immediate and complete haemostasis, resulting in a whole  
20 reabsorption, without incurring adhesions with neighbouring tissues, thus causing  
the correct cicatrisation of the injured tissue. Nevertheless, the techniques so far  
used in manufacturing such haemostatic tissues are very expensive. A large-sized  
fibrin bandage can cost even more than one thousand dollars.

From the publication of C. Clark, "Dried polymerized fibrin sheets arrest  
25 bleeding", Tissue Engineering Weekly, December 28, 1998, News Section, the  
use of liquid fibrin glue consisting of fibrinogen and thrombin is known, the  
utilization whereof is not free from disadvantages. The main disadvantage is the  
difficulty of intervention in certain surgical seats, wherein, in spite of using a  
specific device for their application, instances of overflowing happen prior to the  
30 fibrin solidification.

It is the object of the present invention to provide a process for

- 2 -

manufacturing a fibrin membrane that overcomes said disadvantages. Such an object is achieved by a process, the main characteristics whereof are specified in Claim 1. Further characteristics of the process according to the present invention are specified in the subsequent claims, whereas the properties of the fibrin membrane are specified in claims 6-12.

A first remarkable advantage of the process according to the present invention is that of being quickly and simply feasible, thus providing concrete improvements, even from an economical point of view, with respect to the processes known in the art.

10 A second advantage of the present process derives from the properties of the membrane obtained according to said process, which membrane is completely compatible with the organism whereon it will be applied, being totally extracted from by-products of human or animal blood plasma.

15 Another advantage of the above-mentioned process resides in further properties of the resulting membrane, which shows high adhesiveness, capability of isolating a wound from external contaminant agents and of supporting the cicatrisation process in injured tissues.

20 A further advantage of the above-mentioned process consists in the possibility of packaging under sterile conditions the resulting membrane and preserving it in conditions of unchanged sterility until the time of use, that is until the direct application on the wounded tissue.

25 Further advantages and characteristics of the process according to the present invention and of the fibrin membrane obtained thereby will be clear to those skilled in the art from the following detailed description with reference to the annexed drawings, wherein:

- Fig.1 shows the relationship between specific tension and strain in a specimen of sample A of fibrin membrane, subjected to tensile tests.
- Fig.2 shows the relationship between specific tension and strain in another specimen obtained from the same sample A, subjected to tensile tests.
- 30 - Fig.3 shows an electron microscope image of said sample A.
- Fig.4 shows an infrared spectrum of said sample A.

- 3 -

- Figs.5a and 5b show the relationship between specific tension and strain in two specimens of a same sample B of fibrin membrane, subjected to tensile tests.
- Fig.6 shows an electron microscope image of said sample B.
- 5 - Fig.7 shows an infrared spectrum of said sample B.
- Figs.8a and 8b show the relationship between specific tension and strain in two specimens of a same sample C of fibrin membrane, subjected to tensile tests.
- Fig.9 shows an electron microscope image of said sample C.
- 10 - Fig.10 shows an infrared spectrum of said sample C.

The inventive idea on which the present invention is based is that of having surprisingly found that, by starting from blood plasma as it is or from depleted blood plasma, it is possible to easily and cheaply obtain wholly sterilizable fibrin membranes having physical and structural properties such as to make said  
15 membranes advantageously flexible, mouldable, strongly adhesive on human and animal tissues and soakable with different organic solutions, for example with disinfectant agents, cicatrising agents or drugs for controlled release formulations.

In the present description, by the term "depleted blood plasma" there is meant a by-product of haemoderivative industry, consisting of plasma remaining  
20 from extractions of various protein fractions, such as immunoglobulin, thrombin, antihæmophilic factor, albumin, etc..

The process for manufacturing said fibrin membrane according to the present invention includes the following operating steps:

- a) adding a physiologic coagulant agent solution to depleted blood plasma,  
25 placed in suitable containers;
- b) leaving the mixture to stay up to the formation of a gelatinous blood clot;
- c) removing the transudate from said gelatinous blood clot until obtaining a fibrous membrane;
- 30 d) washing said fibrous membrane with dehydrating and softening agents;
- e) exsiccating said fibrous membrane;

- 4 -

f) sterilizing said fibrous membrane.

In a preferred embodiment of the process according to the present invention, to depleted blood plasma, which was previously stabilized by a solution of an anticoagulant agent, such as sodium citrate, a solution of a clotting agent, such as calcium chloride, is added in an amount suitable to neutralize the amount of  
5 anticoagulant agent.

The so obtained mixture is directly poured into containers suitably sized to satisfy the requirements of use of the final membrane, leaving the whole to stay up to the formation of a gelatinous blood clot.

10 The transudate removing step, that is the removing of the supernatant containing plasmatic proteins, may include several steps in order to remove as much as possible any residues. For this purpose, substances such as inorganic salts (i.e. NaCl, NaHCO<sub>3</sub>, and like), that are completely compatible with human and animal organisms can be used since they are already physiologically present  
15 therein. As a result of the transudate removing step, the blood clot takes the appearance of a fibrous membrane. This one is washed out several times with water and further treated in dehydrating and softening baths, using for example ethanol and propane-triol, in order to absorb even the last water traces.

Then the membrane is left to dry, for example in hot air flow, thereby  
20 obtaining a smooth, flexible, uniform, mouldable, elastic, semitransparent sheet withstanding moderate tensile stresses. The membrane thickness is a function of the layer thickness of plasma and clotting agent mixture, both being initially present in the container for forming the membrane.

The subsequent sterilization step of the dehydrated membrane that can be  
25 performed by means of methods known to those skilled in the art, is preferably carried out:

- in an autoclave, for 20 – 30 min. at 120 – 122°C; or
- according to the "STERRAD" method, using H<sub>2</sub>O<sub>2</sub> for 60 min. at 45°C; or
- by ionizing radiations.

30 In a preferred embodiment of the present invention, a gelatinous quadrangular shaped blood clot is obtained after addition of a calcium chloride

- 5 -

solution to depleted blood plasma, being previously stabilized by sodium citrate. From such blood clot the transudate is removed by using NaCl, then washed 2-3 times with water and subsequently treated with ethanol and propane-triol. The resulting fibrin membrane is dried in hot air flow and sterilized in autoclave for 30 minutes at a temperature of 122°C.

The fibrin membrane obtained according to the above-mentioned process shows the physical properties given in the following operative examples of the invention. The characterization of said membrane is carried out in cooperation with Politecnico di Milano.

#### 10      EXAMPLE 1

130 ml of depleted blood plasma and 10 ml of fresh blood plasma (supplied by Kedrion SpA, Castelveccchio Pascoli, LU, IT) were poured in a suitable rectangular container. An aqueous solution of CaCl<sub>2</sub> 2.6% p/v (using anhydrous CaCl<sub>2</sub>, available on sale) was added at room temperature. Once formed, the blood clot was covered with NaCl powder (available on sale) in order to absorb the transudate and then washed with water. Last operation was repeated 2-3 times. The so obtained membrane was transferred into a bath of propane-triol 10% v/v in ethanol 95% (available on sale) and it was left to stay at room temperature for 16-24 hours.

20      The membrane was extracted, ethanol was evaporated in hot air flow. The membrane was inserted into a closed gas-permeable envelope (available on sale) and then such an envelope was placed in an autoclave for 25-30 minutes at 122°C for sterilization.

#### EXAMPLE 2

25      The rectangular shaped sample A (52 mm x 73 mm) was cut out from a human fibrin membrane obtained according to the above-mentioned process, sterilized in autoclave at 120°C and stored at room temperature. In order to determine the physical properties regarded as critical for the clinical application, sample A was subjected to mechanical tensile and ultimate strength tests, as well as to morphological analysis at the electron microscope, having previously determined the thickness of the membrane.

- 6 -

The specimen thickness was measured by a millesimal micrometer Mitutoyo mod. 293-561-30, S/N 7083373, provided with a friction device allowing to impose high strains with good measurement reproducibility. To avoid damaging sample A, this one was inserted between two Teflon sheets, having measured  
5 thickness equal to 0.142 mm. From the final measurement, that of both Teflon sheets was then subtracted. To check the uniformity level of the considered membrane, thickness measurements were carried out in ten different points of the membrane spaced apart between them and from the edges by about 10 mm. The detected values were as follows:

Sample	Mean thickness ( $\mu\text{m}$ )	Maximum thickness ( $\mu\text{m}$ )	Minimum thickness ( $\mu\text{m}$ )
A	59	72	39

10     Tensile tests

The mechanical properties of sample A were evaluated by monoaxial tensile tests using the equipment MTS Synergie 200 H S/N 261701/30 supplied by MTS (Minneapolis, MN, USA), provided with a cell MTS S/N 2.1279, having 100N as an end-point. From the sample, two test-pieces were cut out using a template, and  
15 the thicknesses thereof were then measured at the barycentre of each test-piece by using the same millesimal micrometer previously used.

Each test-piece was subjected to the following process:

- 20     a) ~~mechanical conditioning by performing of some loading and unloading~~  
cycles between 0 and 1.2N at a sliding crossbar speed corresponding to  
20 mm/min.  
b) breaking strength at a sliding crossbar speed corresponding to 20  
mm/min.

The results of such tests, carried out at room temperature of  $23 \pm 2^\circ\text{C}$ , are represented in Figg. 1 and 2 as a specific tension/strain ratio, whereas for a  
25 quantitative evaluation of both specimen properties the following data are given:

- 7 -

Direction	Thickness ( $\mu\text{m}$ )	Modulus of elasticity K (N/mm)	Proportionality limit $T_P$ (N/mm)	Breaking limit $T_R$ (N/mm)
1	59	0.076	0.040	0.071
2	59	0.413	0.030	0.065

where:

**Direction** denotes the axis along which the tensile strength was exerted: one time along the axis corresponding to the specimen length, another time along the axis corresponding to its width;

5        **T** (N/mm), or specific tension, denotes the ratio between the force applied to the specimen and its width unit (1 mm);

$\epsilon$  (%), or strain, means the percent ratio between the elongation undergone by the specimen and its starting length;

10        **K** (N/mm), or modulus of elasticity, means the ratio between a specific tension increase and a strain increase evaluated in the range between the values corresponding to 30% and 60% of proportionality limit;

**$T_P$**  (N/mm), or proportionality limit, means the limit value of tension, beyond which the tension/strain ratio is no more linear.

**$T_R$**  (N/mm), or breaking limit, the maximum value before breaking.

15        Finally, sample A was observed at the electron microscope: the surface image thereof is shown in Fig. 3.

At last, on sample A an attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectrometry analysis and a Raman spectroscopy analysis were carried out by using a Magna 560 Nicolet spectrophotometer, having an  
20        ATR Model 300 Spectra Tech cell. The resulting spectra relating to sample A are shown in Fig. 4.

### EXAMPLE 3

25        The square shaped sample B (63 mm x 63 mm) was cut out from a human fibrin membrane obtained according to the above-mentioned process, that was sterilized using the STERRAD method (in  $\text{H}_2\text{O}_2$  at  $45^\circ\text{C}$ ) and stored at room temperature. As for sample A, also sample B was subjected to mechanical tensile tests and breaking strength tests, as well as to a morphological analysis at the



electron microscope, after having determined the thickness of the membrane.

For sample B, the same procedure was followed using the same equipment as in Example 2, for the thickness determination. To check the uniformity level of the considered membrane, thickness measurements were carried out in ten different points of the membrane spaced apart between them and from the edges by about 10 mm. The detected values are given as follows:

Sample	Mean thickness ( $\mu\text{m}$ )	Maximum thickness ( $\mu\text{m}$ )	Minimum thickness ( $\mu\text{m}$ )
<b>B</b>	47	56	14

#### Tensile tests

The mechanical properties of sample B were evaluated according to the procedures used in Example 2.

The results of such tests are represented in terms of specific tension/strain ratio in Figs. 5a and 5b, whereas for a quantitative evaluation of properties of both test-pieces, the following data are given:

Specimen	Thickness ( $\mu\text{m}$ )	Modulus of elasticity K (N/mm)	Proportionality limit $T_P$ (N/mm)	Breaking limit $T_R$ (N/mm)
<b>1</b>	47	0.220	0.025	0.033
<b>2</b>	47	0.174	0.025	0.034

In addition, sample B was observed at the electron microscope: the surface image thereof is shown in Fig. 6.

At last, on sample B an attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectrometry analysis was carried out by using the same spectrophotometer as in Example 2. The resulting spectrum relating to sample B is shown in Fig. 7.

#### EXAMPLE 4

The rectangular shaped sample C (66 mm x 128 mm) was cut out from a human fibrin membrane obtained according to the above-mentioned process, that was sterilized in autoclave at 120°C and stored at room temperature. As for samples A and B, also sample C was subjected to mechanical tensile tests and breaking strength tests, as well as to a morphological analysis at the electron microscope, after having determined the thickness of the membrane.

- 9 -

For sample C, the same procedure was followed by using the same equipment as in the Example 2, for determining the thickness. To check the uniformity level of the considered membrane, thickness measurements were carried out in ten different points of the membrane spaced apart between them and from the edges by about 10 mm.

The detected values were as follows:

Sample	Mean thickness ( $\mu\text{m}$ )	Maximum thickness ( $\mu\text{m}$ )	Minimum thickness ( $\mu\text{m}$ )
C	97	111	76

#### Tensile tests

The mechanical properties of sample C were evaluated by the same procedures used in Example 1.

The results of such tests are represented in terms of the specific tension/strain ratio in Figs. 8a and 8b, whereas for a quantitative evaluation of the properties of both test-pieces, the following data are given:

Specimen	Thickness ( $\mu\text{m}$ )	Modulus of elasticity K (N/mm)	Proportionality limit $T_P$ (N/mm)	Breaking limit $T_R$ (N/mm)
1	97	2.525	0.081	0.326
2	97	1.550	0.053	0.210

In addition, sample C was studied at the electron microscope: the surface image thereof is shown in Fig. 9.

At last, on sample C an attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectrometry analysis was carried out by using the same spectrophotometer as in Example 2. The resulting spectrum relating to sample C is shown in Fig. 10.

The test results resumed in the above-given tables and illustrated in the annexed drawings clearly show that by the process according to the present invention, yet starting from a discarded raw material, such as depleted blood plasma, it is possible to obtain a fibrin membrane provided with high mechanical characteristics comparable to those of membranes obtained according to prior art.



- 10 -


## CLAIMS

1. A process for manufacturing a fibrin membrane, characterized in that it comprises the steps of:
  - a) adding a physiological coagulating agent to blood plasma, up to
  - 5 gelling and clot formation;
  - b) removing the transudate from said blood clot by means of physiologic absorbent agents;
  - c) washing said blood clot with dehydrating and softening agents;
  - d) drying and sterilizing said dehydrated blood clot.
- 10 2. The process according to claim 1, characterized in that said physiological clotting agent is calcium chloride.
3. The process according to claim 1 or 2, characterized in that said physiological absorbent agents are inorganic salts.
4. The process according to claim 3, characterized in that said inorganic salts
- 15 are NaCl, NaHCO<sub>3</sub>, or a mixture thereof.
5. The process according to one of the previous claims, characterized in that said softening agents are low-boiling alcohols in propane-triol, in particular ethanol in propane-triol.
6. A fibrin membrane, characterized in that it is obtained by a process
- 20 according to one or more previous claims.
7. The fibrin membrane according to claim 6, characterized in that it shows a modulus of elasticity between 0.070 and 2.600 N/mm.
8. The fibrin membrane according to claim 6 or 7, characterized in that it shows a breaking limit between 0.030 and 0.350 N/mm.
- 25 9. The fibrin membrane according to one or more claims from 6 to 8, characterized in that it shows a proportionality limit tension/strain between 0.025 and 0.085 N/mm.
10. The fibrin membrane according to one or more claims from 6 to 9, characterized in that it is soaked with disinfectant agents.
- 30 11. The fibrin membrane according to one or more claims from 6 to 10, characterized in that it is soaked with drugs.

- 11 -

12. The fibrin membrane according to one or more claims from 6 to 11, characterized in that it is soaked with tissue growth factors.


Fig. 1Fig. 2





10µm


*Fig. 3*

BEST AVAILABLE COPY

Fig. 4

Fig. 5aFig. 5b








10µm

Fig. 6

BEST AVAILABLE COPY

**Fig. 7**

7/9

Fig. BaFig. Bb





Fig. 9

BEST AVAILABLE COPY

9/9

**Fig. 10**

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/IT 03/00780

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C08J5/22 C08J5/18 A61L24/10 A61L26/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C08J A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/131933 A1 (DELMOTTE YVES) 19 September 2002 (2002-09-19) paragraphs '0089!', '0090!; examples	6-12
A	US 6 368 298 B1 (LODI SERGIO ET AL) 9 April 2002 (2002-04-09) claim 1	1-12

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the International filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the International filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the International search

30 June 2004

Date of mailing of the International search report

09/07/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

West, N

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No  
PCT/IT 03/00780

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002131933 A1	19-09-2002	US 6599515 B1	29-07-2003
		US 6461325 B1	08-10-2002
		WO 03035115 A2	01-05-2003
		AT 244584 T	15-07-2003
		AU 697045 B2	24-09-1998
		AU 4536296 A	07-08-1996
		DE 69629010 D1	14-08-2003
		DE 69629010 T2	15-04-2004
		EP 0804257 A1	05-11-1997
		JP 11502431 T	02-03-1999
		US 5989215 A	23-11-1999
		US 6074663 A	13-06-2000
		AU 6135901 A	20-11-2001
		EP 1395298 A2	10-03-2004
		WO 0185225 A2	15-11-2001
		AU 3720097 A	09-02-1998
		EP 0917444 A1	26-05-1999
		WO 9802098 A1	22-01-1998
US 6368298 B1	09-04-2002	IT MI971490 A1	24-12-1998
		AU 7931998 A	04-01-1999
		WO 9858689 A1	30-12-1998
		US 2002169408 A1	14-11-2002
		US 2004071786 A1	15-04-2004